---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-026192"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:19:32.124491+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Received Nasdaq notice on Feb 10, 2025, that average closing bid price was below $1.00 for 31 consecutive trading days.
- Company has 180 days, until Aug 11, 2025, to regain compliance by closing at $1.00 for 10 consecutive business days.
- No immediate impact on listing; common stock continues to trade on Nasdaq while options to cure are explored.
- If not cured by Aug 11, Ovid may seek a second 180-day period by transferring to Nasdaq Capital Market.
- Failure to cure could lead to delisting, with appeal rights to a Nasdaq Hearings Panel.

## SEC filing metadata
- accession: 0001193125-25-026192
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/d385884d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-026192
- JSON: https://secwatch.observer/filing/0001193125-25-026192.json
- Plain text: https://secwatch.observer/filing/0001193125-25-026192.txt

## Source-grounded claims
- claim_id: b3396308313fca05b9a27140187e4bf096b88184
  claim: Ovid Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  evidence_excerpt: February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.